Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

STADA Arzneimittel AG

https://www.stada.com/

Latest From STADA Arzneimittel AG

Alvotech Files Higher-Strength Adalimumab In US And EU

Alvotech has announced the filing of its AVT02 higher-strength adalimumab version of Humira 100mg/ml with both the FDA and the EMA, as well as disclosing expected decision dates. Teva will market the biosimilar in the US and Stada in Europe.

Biosimilars Strategy

A Year Of Surprises Shakes Up Off-Patent Industry

After an eventful year for the off-patent industry, the world’s leading generics and biosimilars players have switched places in Generics Bulletin’s newly compiled global sales ranking.

Biosimilars Generic Drugs

Stada Takes ViruProtect To Russia And Beyond

Germany's Stada has expanded its deal with Enymatica to take the latter's ViruProtect common cold brand into Russia, the CIS and beyond.

Deals OTC Devices

Thinking About Entering The EU CBD Market? Some Food For Thought

Consumer health companies are starting to step into the lucrative but fast-changing and complex EU cannabidiol market. But what are the key considerations for firms before making such a move, or if they have already? HBW Insight speaks to CBD regulatory expert Greer Deal. 

Wellness Dietary Supplements
See All

Company Information

UsernamePublicRestriction

Register